FDA’s Off-Label Reprint Guidance Is Unlikely To Clarify Anything Very Soon
Executive Summary
Companies hoping that the end of the comment period for FDA's draft guidance on "good reprint practices" will swiftly produce a final roadmap should probably not hold their breath